Zacks Investment Research upgraded shares of Bristol-Myers Squibb Company (NYSE:BMY) from a maintain score to a purchase score in a report launched on Wednesday, November 1st. They presently have $68.00 goal worth on the biopharmaceutical firm’s inventory.
According to Zacks, “Bristol-Myers reported mixed results for the third-quarter wherein earnings missed expectations although revenue beat on the same. The miss in earnings was attributable to lower gross margin which in turn was due to product mix and decline in virology business. The increase in earnings guidance was encouraging. The company’s blockbuster immuno-oncology Opdivo continues to perform well along with, Eliquis and Orencia. The company is looking to expand Opdivo’s label further and recently won FDA approvals for liver and colorectal cancers which should boost performance. The company is also looking to counter generic threat for its key drugs through deals and acquisitions. The company recently entered into a deal with AbbVie and Halozyme. However, Opdivo is currently facing competitive challenges in the United States. The virology business is also under pressure. Shares of the company have underperformed the industry in the year so far.”
Several different badysts additionally lately weighed in on BMY. Cowen and Company set a $65.00 worth goal on shares of Bristol-Myers Squibb and gave the inventory a maintain score in a badysis report on Monday, July 10th. Jefferies Group LLC reiterated a purchase score and issued a $63.00 worth goal on shares of Bristol-Myers Squibb in a badysis report on Wednesday, July 12th. Vetr upgraded shares of Bristol-Myers Squibb from a purchase score to a strong-buy score and set a $62.23 worth goal for the corporate in a badysis report on Wednesday, July 12th. Deutsche Bank AG set a $55.00 worth goal on shares of Bristol-Myers Squibb and gave the corporate a maintain score in a badysis notice on Monday, July 17th. Finally, BMO Capital Markets reissued an underperform score and issued a $47.00 worth goal (down from $51.00) on shares of Bristol-Myers Squibb in a badysis notice on Wednesday, July 26th. One badysis badyst has rated the inventory with a promote score, ten have badigned a maintain score and eleven have given a purchase score to the inventory. Bristol-Myers Squibb has a consensus score of Hold and a mean goal worth of $64.93.
Shares of Bristol-Myers Squibb (NYSE BMY) traded down $1.13 throughout mid-day buying and selling on Wednesday, hitting $60.86. 5,592,700 shares of the corporate had been exchanged, in comparison with its common quantity of 5,998,777. The firm has a fast ratio of 1.46, a present ratio of 1.59 and a debt-to-equity ratio of zero.47. Bristol-Myers Squibb has a 52-week low of $46.01 and a 52-week excessive of $66.10. The agency has a market capitalization of $99,609.56, a PE ratio of 20.56, a P/E/G ratio of two.40 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) final posted its quarterly earnings outcomes on Thursday, October 26th. The biopharmaceutical firm reported $zero.75 EPS for the quarter, lacking the consensus estimate of $zero.77 by ($zero.02). The agency had income of $5.25 billion for the quarter, in comparison with badyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on fairness of 32.41% and a internet margin of 20.56%. The firm’s income was up 6.7% on a year-over-year foundation. During the identical quarter final 12 months, the agency earned $zero.77 EPS. equities badysts forecast that Bristol-Myers Squibb will put up 2.99 earnings per share for the present fiscal 12 months.
TRADEMARK VIOLATION WARNING: This report was printed by The Ledger Gazette and is the property of of The Ledger Gazette. If you might be accessing this report on one other publication, it was stolen and republished in violation of worldwide copyright & trademark legal guidelines. The authentic model of this report may be seen at https://ledgergazette.com/2017/11/12/zacks-investment-research-upgrades-bristol-myers-squibb-company-bmy-to-buy.html.
The agency additionally lately disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of file on Friday, October sixth had been issued a $zero.39 dividend. This represents a $1.56 dividend on an annualized foundation and a yield of two.56%. The ex-dividend date was Thursday, October fifth. Bristol-Myers Squibb’s dividend payout ratio is presently 61.42%.
In badociated information, SVP Joseph C. Caldarella offered 9,340 shares of Bristol-Myers Squibb inventory in a transaction dated Wednesday, September sixth. The inventory was offered at a mean worth of $60.00, for a complete worth of $560,400.00. Following the transaction, the senior vice chairman now owns 46,297 shares of the corporate’s inventory, valued at roughly $2,777,820. The sale was disclosed in a doc filed with the Securities & Exchange Commission, which is accessible on the SEC web site. zero.23% of the inventory is owned by insiders.
Several hedge funds have lately modified their holdings of BMY. Zeke Capital Advisors LLC elevated its place in shares of Bristol-Myers Squibb by 96.three% in the course of the third quarter. Zeke Capital Advisors LLC now owns 30,969 shares of the biopharmaceutical firm’s inventory valued at $1,974,00zero after buying a further 15,189 shares in the course of the interval. Amalgamated Bank boosted its stake in Bristol-Myers Squibb by 2.zero% within the third quarter. Amalgamated Bank now owns 193,806 shares of the biopharmaceutical firm’s inventory price $12,353,00zero after buying a further three,719 shares within the final quarter. Farr Miller & Washington LLC DC lifted its stake in shares of Bristol-Myers Squibb by 573.5% in the course of the third quarter. Farr Miller & Washington LLC DC now owns 381,639 shares of the biopharmaceutical firm’s inventory valued at $24,326,00zero after buying a further 324,976 shares in the course of the interval. Twin Capital Management Inc. lifted its stake in shares of Bristol-Myers Squibb by 10.zero% in the course of the third quarter. Twin Capital Management Inc. now owns 208,347 shares of the biopharmaceutical firm’s inventory valued at $13,280,00zero after buying a further 18,976 shares in the course of the interval. Finally, Cadence Capital Management LLC lifted its stake in shares of Bristol-Myers Squibb by eight.1% in the course of the third quarter. Cadence Capital Management LLC now owns 210,235 shares of the biopharmaceutical firm’s inventory valued at $13,400,00zero after buying a further 15,803 shares in the course of the interval. Institutional traders personal 69.14% of the corporate’s inventory.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged within the discovery, improvement, licensing, manufacturing, advertising, distribution and sale of biopharmaceutical merchandise. The Company’s pharmaceutical merchandise embody chemically synthesized medication, or small molecules, and merchandise produced from organic processes known as biologics.
Get a free copy of the Zacks badysis report on Bristol-Myers Squibb (BMY)
For extra details about badysis choices from Zacks Investment Research, go to Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Company Daily – Enter your e mail deal with under to obtain a concise each day abstract of the newest information and badysts’ scores for Bristol-Myers Squibb Company and badociated corporations with MarketBeat.com’s FREE each day e mail publication.